[October 28, 2016]

Global Meningococcal Vaccines Drug Forecast and Market Analysis to 2025 - Research and Markets

Research and Markets has announced the addition of the "PharmaPoint: Meningococcal Vaccines - Global Drug Forecast and Market Analysis to 2025" report to their offering.

Pharmaceutical companies have developed vaccines addressing the most urgent medical needs based on clinical efficacy and epidemiology. The resulting vaccines can be divided into three categories, although other and finer segmentations can be made. These three categories include monovalent vaccines targeting serogroup C (MenC vaccines), vaccines protecting against most serogroup B strains (MenB vaccines), and tetravalent vaccines protecting against serogroups A, C, W, and Y (MenACWY vaccines). While the MenB vaccines use recombinant proteins as antigens, all other meningococcal vaccines are based on the polysaccharide capsules of the various serogroups.

Key Questions Answered

• Based on interviews with key opinion leaders (KOLs), GlobalData has identified key unmet needs in the meningococcal vaccine marketplace.
• What will be the effect of recent and upcoming changes in national immunization schedules?
• How will the new fist-in-class vaccine covering all main serogroups (MenABCWY) be received in the different markets?
• What research and development (R&D) strategies will companies leverage to compete in the future meningococcal vaccine marketplace?
• Which patient population(s) are most likely to be targeted for vaccines against serogroup B and the pentavalent MenABCWY pipeline vaccine?

• The meningococcal vaccine market in the US, 5EU, Japan, and Brazil to grow from approximately $1.1bn in 2015 to $1.8bn in 2025, at a compound annual growth rate (CAGR) of 5.4%. This growth across the 8MM will primarily be driven by the introduction of additional meningococcal vaccines into the national routine infant and adolescent vaccination schedules in some 5EU countries. Further growth will be the result of the launch of a pentavalent MenABCWY vaccine during the forecast period while the commercial meningococcal vaccine markets in Brazil and Japan will experience a decline at a negative CAGR of 1.8% and 0.9% respectively.
• With most countries in the 8MM using serogroup B vaccines only for individuals at high risk of contracting meningococcal disease, the routine application of these protein-based vaccines is seen as the major unmet need to be addressed in the oncoming years.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Disease Management

6 Competitive Assessment

7 Unmet Needs and Opportunities

8 Pipeline Assessment

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

• GlaxoSmithKline
• Sanofi
• Pfizer
  

For more information about this report visit http://www.researchandmarkets.com/research/glczwk/pharmapoint

View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005427/en/

[ Back To TMCnet.com's Homepage ]